In this study, we comprehensively characterized the biologically relevant MET alterations—amplification and exon 14 skipping—in a large cohort of 474 NSCLC samples using of a RNA‐based technology (nCounter; Fig. 5) and we systematically compared the results with other currently available methods for MET testing. The gene discussed is MET; the disease is non-small cell lung carcinoma.